New study aims to catch Alzheimer's sooner by looking at the whole person

NCT ID NCT07399418

Recruiting now Knowledge-focused Sponsor: Istituti Clinici Scientifici Maugeri SpA Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

The TRIAD study is testing whether combining biological markers, psychological tests, and social factors can help diagnose Alzheimer's disease earlier and more accurately. Researchers will follow 80 patients with cognitive decline and their caregivers, collecting data through memory tests, blood samples, brain scans, and questionnaires. The goal is to create a more complete picture of the disease to improve early detection and care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this study could lead to better early detection tools for Alzheimer's disease by integrating multiple risk factors.
What could go wrong: This is an observational study with only 80 participants, so results may not apply to everyone. It aims to gather knowledge, not test a treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COGNITIVE DECLINE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease Cognitive Dysfunction disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COGNITIVE DECLINE

Contacts and locations

Locations

ICS Maugeri Montescano Institute
RECRUITING

Montescano, Pavia, Italy, 27040, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.